Camrelizumab and Famitinib Combo, Effective Against Advanced Renal Cell Carcinoma, Study Finds

According to the findings of a phase II basket research, blocking immunological checkpoints and angiogenesis with camrelizumab and famitinib looks to be a potential method in the treatment of advanced or metastatic renal cell carcinoma (RCC).

Camrelizumab and Famitinib Combo, Effective Against Advanced Renal Cell Carcinoma, Study Finds
Photo: Doctor with a Cancer Patient | InStyleHealth

The research comprised 38 patients with advanced or metastatic RCC, 13 (34.2%) of whom were therapy-naive and 25 (65.8%) of whom had previously undergone treatment. Camrelizumab (200 mg intravenously every 3 weeks) and famitinib were given to all of them (20 mg orally once daily).

23 patients had a confirmed objective response after a median monitoring duration of 16.5 months (range, 6.1–20.4). The objective response rate (ORR) for this study was 60.5 percent (95 percent confidence interval [CI], 43.4–76.0). At the data cutoff, 18 (78.3%) patients' responses were still ongoing, and the Kaplan–Meier predicted median length of response had not yet been attained (range, 1.0 to 14.8 months).

PFS was 14.6 months on average (95 percent confidence interval: 6.2–not attained).

The treatment-naive group (84.6 percent, 95 percent CI, 54.6–98.1) had a higher ORR than the pretreated group (48.0 percent, 95 percent CI, 27.8–68.7) in subgroup analysis. In the first, the median PFS was not attained, while in the second, it was 13.4 months (95 percent confidence interval, 4.1–not reached).

Proteinuria (18.4%), hypertension (18.4%), reduced neutrophil count (13.2%), palmar-plantar erythrodysesthesia syndrome (10.5%), and hypertriglyceridemia were the most common grade 3 or 4 treatment-related side events in terms of safety (10.5 percent).

There were no deaths reported as a result of the treatment, and no new safety signals were discovered.

Source: Clin Cancer Res 2021;doi:10.1158/1078-0432.CCR-21-1698

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post